What the Biggest Investors Are Doing About Opko Health Stock's Dismal Performance

What the Biggest Investors Are Doing About Opko Health Stock's Dismal Performance

So far in 2017, Opko Health (NASDAQ: OPK) has lost roughly one-third of its market cap. The stock finished 2016 down 7% due to an end-of-year plunge.

Things aren't going well for multiple reasons. That big drop at the end of last year stemmed from disappointing results from a late-stage study of Opko's experimental long-acting human growth hormone product (hGH-CTP) in adults. The company's 2015 acquisition of Bio-Reference Labs still doesn't appear to be paying off. The launch for its secondary hyperparathyroidism (SHPT) drug Rayaldee has been sluggish. 

Around 17% of Opko Health stock is owned by institutions and funds. With all of the company's woes, what are these big investors doing about Opko?

Continue reading

Source: Fool.com